Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Zeria to Launch Hypophosphatemia Treatment Phosribbon Combination Granules on March 4
February 25, 2013
- MTPC Calls for Proper Use of Telavic Following Reports of Serious Infections
February 25, 2013
- LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
- Lotriga, Equa, Aimix Most Promoted Products in GP, HP Markets in January: Rep Track Survey
February 22, 2013
- Astellas Files for Additional Indication for Dormicum Based on Data from Public Domain
February 22, 2013
- Shionogi Settles Lawsuit over Royalties Payment with US Firm InterMune
February 22, 2013
- Shire Appoints Steve Engen as Representative Director of Japanese Subsidiary
February 22, 2013
- Actelion Receives Approval for Generic Version of Flolan
February 22, 2013
- Chugai Sues 4 Companies Including Iwaki Seiyaku for Patent Infringement Related to Oxarol Ointment
February 21, 2013
- HIV Treatment Dolutegravir Gets FDA Priority Review: ViiV Healthcare
February 21, 2013
- Radium-223 Granted Priority Review Status by US FDA: Bayer HealthCare
February 19, 2013
- DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
- Blopress Retakes Top Spot in Domestic Ethical Drug Market in 2012: IMS Japan
February 19, 2013
- Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
- No Statistical Significance Shown in OS between Tivozanib and Sorafenib in PIII Study: Astellas
February 18, 2013
- Nihon Medi-Physics to Establish New Manufacturing Base for PET Diagnostics in Fujioka City, Gunma Prefecture
February 18, 2013
- Small and Medium Sized Pharmacies Jointly Buys Generics Directly from Manufacturers
February 15, 2013
- Takeda Subsidiary Suspends Operations for 12 Days Due to Alinamin-F5 Injection Recalls
February 15, 2013
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
- Nichi-Iko to Open Representative Office in Thailand on April 1
February 14, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…